susvimo- ranibizumab injection, solution
genentech, inc. - ranibizumab (unii: zl1r02vt79) (ranibizumab - unii:zl1r02vt79) - susvimo (ranibizumab injection) is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (amd) who have previously responded to at least two intravitreal injections of a vascular endothelial growth factor (vegf) inhibitor medication. susvimo (ranibizumab injection) is contraindicated in patients with ocular or periocular infections. susvimo (ranibizumab injection) is contraindicated in patients with active intraocular inflammation. susvimo (ranibizumab injection) is contraindicated in patients with known hypersensitivity to ranibizumab products or any of the excipients in susvimo (ranibizumab injection). risk summary there are no adequate and well-controlled studies of susvimo (ranibizumab injection) administration in pregnant women. administration of ranibizumab to pregnant monkeys throughout the period of organogenesis resulted in a low incidence of skeletal abnormalities at intravitreal doses up to 41 times the human exposure (based on serum levels following the re
susvimo solution
hoffmann-la roche limited - ranibizumab - solution - 100mg - ranibizumab 100mg
dronate 4mg/5ml concentrate solution for iv infusion
i.e. medica, inc.; distributor: i.e. medica, inc. - zoledronic acid (as monohydrate) - concentrate solution for iv infusion - 4mg/5ml
none 4 mg/5 ml concentrate solution for iv infusion
l.e. medica, inc.; distributor: l.e. medica, inc. - zoledronic acid (as monohydrate) - concentrate solution for iv infusion - 4 mg/5 ml
cenride 10
usv centra - amisulpride - 100mg - 10
cenride 10
usv centra - amisulpride - 200mg - 10
censpram plus 10 tab
usv (centra) - escitalopram,clonazepam - tab - 10,0.5;mg - 10
citinerve 10 tab
usv centra - citicoline - tab - 500mg - 10
citinrrve 2ml inj
usv centra - citicoline - inj - (+methyl paraben,propyl paraben) - 2ml